EU approved Moderna’s COVID-19 vaccine

EU approved Moderna’s COVID-19 vaccine

EU approved Moderna’s COVID-19 vaccine. Following the approval at the end of December for the use of the COVID-19 vaccine developed by the German biotech company and the US Pfizer Pharmaceutical Co., Ltd., the European Union approved the use of the Moderna COVID-19 vaccine on January 6, allowing the vaccine to be placed on the EU market.

According to the announcement issued by the European Commission on the same day, after a comprehensive assessment of the safety, effectiveness and quality of the vaccine, the European Medicines Agency gave a “positive opinion” to the Moderna COVID-19 vaccine. In addition, the EU member states have no objection. The committee decided to approve the conditional listing of Moderna’s COVID-19 vaccine on the EU market.

The announcement showed that before Moderna’s listing application was filed on November 30 last year, the European Medicines Agency had initiated a “rolling review” to evaluate the Moderna COVID-19 vaccine to speed up the approval process; it was once reported to Europe on January 4 The Drug Administration may complete the approval ahead of schedule, but in the end the approval result will be made public on January 6 as originally planned.

Like the COVID-19 vaccine developed by the German biotech company and the American Pfizer Pharmaceutical Co., Ltd., the Moderna COVID-19 vaccine also uses messenger ribonucleic acid (mRNA). On November 16 last year, Moderna announced that its vaccine’s effectiveness reached 94.5%, and it does not require ultra-low temperature storage. It can be stored at a temperature of 2 to 8 degrees Celsius (the temperature of a general refrigerator freezer) for 30 days, at a temperature of minus 20 degrees Celsius. Stored in 6 months.

On November 24 last year, the European Union announced an agreement with Moderna to order 160 million doses of Moderna’s COVID-19 vaccine. Moderna promised to deliver the vaccine from the first quarter to the third quarter of 2021; according to the EU plan, January 6 After approval for use, if Moderna delivers the vaccine as scheduled, the European Union will then distribute the vaccine to member states at the same time, under the same conditions, and in proportion to the population.

In addition to the Moderna COVID-19 vaccine, the European Union approved the use of the vaccine developed by the German biotech company and the US Pfizer Pharmaceutical Co., Ltd. on December 21 last year. The current order for this vaccine is 300 million doses; overall, it is included. Agreements reached with AstraZeneca, Sanofi and GlaxoSmithKline in the United Kingdom, Janssen Pharmaceuticals under Johnson & Johnson in the United States, and CureVac in Germany. The EU is now ordering nearly 2 billion doses of COVID-19 vaccine. Each citizen of the EU member states will receive about 4 doses of vaccine.

(source:internet, reference only)

Disclaimer of medicaltrend.org